REGULATORY REQUIREMENTS FOR GENERIC DRUGS USED IN THE UNITED STATES OF AMERICA: A COMPREHENSIVE ANALYSIS OF THE FDA APPROVAL FRAMEWORK

Pavithra Bandi

Bandi Pavithra Department of Pharmaceutical Regulatory Affairs, Hindu College of Pharmacy, Amaravati Road, Guntur.
lapinpress@gmail.com

Abstract

Generic drugs have transformed the United States healthcare system by providing safe, effective, and affordable alternatives to innovator pharmaceutical products. The regulatory approval of generic medicines is governed by the United States Food and Drug Administration (FDA) through the Abbreviated New Drug Application (ANDA) pathway established under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch–Waxman Act. The introduction of this regulatory pathway significantly accelerated generic drug availability while preserving rigorous standards for pharmaceutical quality, safety, efficacy, and therapeutic equivalence. Since its implementation, generic medicines have substantially reduced healthcare expenditures and expanded patient access to essential medications. This review comprehensively examines the regulatory framework governing generic drug approval in the United States, including the historical evolution of generic drug legislation, the structure and requirements of the ANDA process, bioequivalence standards, Chemistry, Manufacturing, and Controls (CMC) requirements, current Good Manufacturing Practice (cGMP) compliance, patent certification procedures, Orange Book listings, labeling requirements, post-marketing surveillance, and recent regulatory developments under the Generic Drug User Fee Amendments (GDUFA). The review further discusses the scientific principles underlying bioequivalence, regulatory challenges associated with complex generic drugs, supply chain considerations, and future perspectives for generic drug regulation. The United States regulatory framework continues to evolve in response to advances in pharmaceutical science while maintaining a balance between encouraging pharmaceutical innovation and facilitating timely market access for cost-effective generic medicines. A comprehensive understanding of these regulatory requirements is essential for regulatory professionals, pharmaceutical scientists, academic researchers, healthcare providers, and policy makers involved in generic drug development and approval.

Keywords: Generic drugs, Food and Drug Administration, Abbreviated New Drug Application, Bioequivalence, Hatch–Waxman Act, Generic Drug User Fee Amendments, Therapeutic equivalence, Pharmaceutical regulation

Downloads

Download data is not yet available.

References

1. U.S. Food and Drug Administration. Abbreviated New Drug Application (ANDA) [Internet]. Silver Spring (MD): FDA; 2025 [cited 2026 Jun 26]. Available from: FDA ANDA page
2. U.S. Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations (Orange Book) [Internet]. Silver Spring (MD): FDA; 2025 [cited 2026 Jun 26]. Available from: FDA Orange Book
3. U.S. Food and Drug Administration. Orange Book preface [Internet]. Silver Spring (MD): FDA; 2025 [cited 2026 Jun 26]. Available from: Orange Book Preface
4. United States. Federal Food, Drug, and Cosmetic Act. 21 USC §301 et seq.
5. United States. Code of Federal Regulations. Title 21. Part 314. Applications for FDA approval to market a new drug.
6. United States. Code of Federal Regulations. Title 21. Part 320. Bioavailability and bioequivalence requirements.
7. United States. Code of Federal Regulations. Title 21. Parts 210 and 211. Current good manufacturing practice for finished pharmaceuticals.
8. U.S. Food and Drug Administration. Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. Silver Spring (MD): FDA.
9. U.S. Food and Drug Administration. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Silver Spring (MD): FDA.
10. U.S. Food and Drug Administration. Product-specific guidances for generic drug development [Internet]. Silver Spring (MD): FDA [cited 2026 Jun Available from: Product-specific guidance resources
11. U.S. Food and Drug Administration. Guidance for industry: Referencing approved drug products in ANDA submissions. Silver Spring (MD): FDA.
12. U.S. Food and Drug Administration. Guidance for industry: ANDA submissions-content and format. Silver Spring (MD): FDA.
13. U.S. Food and Drug Administration. Guidance for industry: Good ANDA submission practices. Silver Spring (MD): FDA.
14. U.S. Food and Drug Administration. Orange Book questions and answers: Guidance for industry [Internet]. Silver Spring (MD): FDA; 2022 [cited 2026 Jun 26]. Available from: Orange Book Q&A Guidance
15. U.S. Food and Drug Administration. Generic drug labeling resources [Internet]. Silver Spring (MD): FDA [cited 2026 Jun 26]. Available from: Generic drug labeling resources
16. International Council for Harmonisation. M4: Organisation of the common technical document for the registration of pharmaceuticals for human use. Geneva: ICH.
17. International Council for Harmonisation. Q1A(R2): Stability testing of new drug substances and products. Geneva: ICH.
18. International Council for Harmonisation. Q2(R2): Validation of analytical procedures. Geneva: ICH.
19. International Council for Harmonisation. Q8(R2): Pharmaceutical development. Geneva: ICH.
20. International Council for Harmonisation. Q9(R1): Quality risk management. Geneva: ICH.
21. International Council for Harmonisation. Q10: Pharmaceutical quality system. Geneva: ICH.
22. International Council for Harmonisation. Q12: Technical and regulatory considerations for pharmaceutical product lifecycle management. Geneva: ICH.
23. Shargel L, Yu ABC. Applied biopharmaceutics and pharmacokinetics. 8th ed. New York: McGraw-Hill Education; 2022.
24. Aulton ME, Taylor KMG. Aulton's pharmaceutics: the design and manufacture of medicines. 6th ed. London: Elsevier; 2022.
25. Allen LV Jr. Remington: the science and practice of pharmacy. 23rd ed. London: Pharmaceutical Press; 2020.
26. U.S. Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations. 46th ed. Silver Spring (MD): FDA; 2026.
27. U.S. Food and Drug Administration. Generic drugs: questions and answers [Internet]. Silver Spring (MD): FDA.
28. Grabowski H, Vernon J. Longer patents for increased generic competition in the United States: the Hatch-Waxman Act after one decade. Pharmacoeconomics. 1996;10 Suppl 2:110-23.
29. Mossinghoff GJ. Overview of the Hatch-Waxman Act and its impact on the drug development process. Food Drug Law J. 1999;54(2):187-94.
30. Berndt ER, Conti RM, Murphy SJ. The Generic Drug User Fee Amendments: an economic perspective. J Law Econ. 2018;61(3):389-426.
31. Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother. 2009;43(10):1583-97.
32. Midha KK, McKay G. Bioequivalence: its history, practice, and future. AAPS J. 2009;11(4):664-70.
33. Yu LX, Jiang W, Zhang X, Lionberger R, Makhlouf F, Schuirmann DJ, et al. Novel bioequivalence approach for orally inhaled drug products. Clin Pharmacol Ther. 2015;97(6):598-600.
34. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-20.
35. Shah VP, Midha KK, Findlay JWA, Hill HM, Hulse JD, McGilveray IJ, et al. Bioanalytical method validation—a revisit with a decade of progress. Pharm Res. 2000;17(12):1551-7.
36. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res. 2002;19(7):921-5.
37. Lionberger RA. Innovation in generic drug development and regulatory science. Clin Pharmacol Ther. 2008;83(6):1031-3.
38. Lionberger RA, Lee SL, Lee L, Raw A, Yu LX. Quality by design: concepts for ANDAs. AAPS J. 2008;10(2):268-76.
39. Yu LX, Lionberger R, Raw A, D'Costa R, Wu H, Hussain A. Applications of process analytical technology to drug quality. AAPS J. 2004;6(3):E35.
40. ICH Steering Committee. ICH harmonised tripartite guideline: pharmaceutical quality system Q10. Geneva: ICH.
41. Waterman KC, Adami RC. Accelerated aging: prediction of chemical stability of pharmaceuticals. Int J Pharm. 2005;293(1-2):101-25.
42. U.S. Food and Drug Administration. Guidance for industry: Revising ANDA labeling following revision of the RLD labeling. Silver Spring (MD): FDA.
43. Hickey KJ. Skinny labels for generic drugs under Hatch-Waxman. Congressional Research Service; 2024.
44. Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of pharmaceutical excipients. 9th ed. London: Pharmaceutical Press; 2020.
45. U.S. Food and Drug Administration. Guidance for industry: Changes to an approved NDA or ANDA. Silver Spring (MD): FDA.
46. U.S. Food and Drug Administration. FDA adverse event reporting system (FAERS): latest quarterly data files [Internet]. Silver Spring (MD): FDA.
47. U.S. Food and Drug Administration. Drug shortages [Internet]. Silver Spring (MD): FDA.
48. Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res. 2008;25(4):781-91.
49. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15(6):657-80.
50. U.S. Food and Drug Administration. Generic Drug User Fee Amendments (GDUFA) [Internet]. Silver Spring (MD): FDA [cited 2026 Jun 26]. Available from: GDUFA resources